13 Jan 2026 | 5 Mins Read
Delhi High Court allows cheaper Nivolumab biosimilar sale
Flipitmoney
The Delhi High Court has allowed Zydus Lifesciences to manufacture and sell a biosimilar version of Bristol Myers Squibb's cancer drug Nivolumab, priced nearly 70% lower, citing public interest. Justices C Hari Shankar and Om Prakash Shukla overruled a previous ruling and directed Zydus to maintain sales records until the patent expires on May 2, 2026.